Payment overview · 2025
General Payments
$1,048.89
30 reported records · 13 companies
Healthcare provider profile · identity verified
Lara Le, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ESCONDIDO, CA · NPI 1043239841
Verified facts
What the public records show
CMS Open Payments records show Lara Le, MD received $1,048.89 in general payments during 2025 across 30 reported records.
GlaxoSmithKline, LLC. accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $296.85 | 28.3% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $238.76 | 22.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $188.04 | 17.9% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $140.59 | 13.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $32.08 | 3.1% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $27.95 | 2.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $27.89 | 2.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.27 | 2.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.61 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.99 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.69 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.60 | 1.4% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $9.57 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,046.89 | 29 |
| Travel and Lodging | $2.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $188.77 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $140.59 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $122.00 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.76 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $118.00 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $93.66 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $79.28 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.04 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.05 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $32.08 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $27.89 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $9.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
30 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 323 | 98 |
| Lisinopril | Lisinopril | 234 | 70 |
| Losartan Potassium | Losartan Potassium | 197 | 63 |
| Gabapentin | Gabapentin | 190 | 54 |
| Metformin Hcl | Metformin Hcl | 187 | 56 |
| Montelukast Sodium | Montelukast Sodium | 180 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 55 |
| Eliquis | Apixaban | 158 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 48 |
| Furosemide | Furosemide | 132 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 39 |
| Spironolactone | Spironolactone | 102 | 31 |
| Celecoxib | Celecoxib | 101 | 39 |
| Valsartan | Valsartan | 100 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 42 |
| Ezetimibe | Ezetimibe | 94 | 27 |
| Famotidine | Famotidine | 91 | 39 |
| Trazodone Hcl | Trazodone Hcl | 86 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 24 |
| Omeprazole | Omeprazole | 80 | 32 |
| Simvastatin | Simvastatin | 77 | 25 |
| Ozempic | Semaglutide | 75 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 71 | 24 |
| Synthroid | Levothyroxine Sodium | 71 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 21 |
| Alprazolam | Alprazolam | 66 | 22 |
| Alendronate Sodium | Alendronate Sodium | 64 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 19 |
| Azithromycin | Azithromycin | 63 | 57 |
| Carvedilol | Carvedilol | 63 | 22 |
| Potassium Chloride | Potassium Chloride | 63 | 25 |
| Atenolol | Atenolol | 62 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 19 |
| Mirtazapine | Mirtazapine | 56 | 17 |
| Prednisone | Prednisone | 56 | 28 |
| Fenofibrate | Fenofibrate | 54 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 24 |
| Estradiol | Estradiol | 52 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 48 | 13 |
| Baclofen | Baclofen | 47 | 24 |
| Bupropion Xl | Bupropion Hcl | 45 | 12 |
| Cephalexin | Cephalexin | 45 | 39 |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 12 |
| Mupirocin | Mupirocin | 43 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 11 |
| Allopurinol | Allopurinol | 41 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 40 | 13 |
| Hydrocortisone | Hydrocortisone | 39 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Jardiance | Empagliflozin | 33 | 11 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Prolia | Denosumab | 30 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | 11 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 25 |
| Tramadol Hcl | Tramadol Hcl | 25 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 18 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Livalo | Pitavastatin Calcium | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 14 |
| Digoxin | Digoxin | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Misoprostol | Misoprostol | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Meloxicam | Meloxicam | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Euthyrox | Levothyroxine Sodium | 17 | suppressed |
| Progesterone | Progesterone, Micronized | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 15 |
| Naratriptan Hcl | Naratriptan Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Osphena | Ospemifene | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,048.89 · 30 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, CAPVAXIVE, ENFLONSIA, EVENITY, GARDASIL 9, GEMTESA, KISUNLA, Kerendia, MOUNJARO, REXULTI, SHINGRIX, TRELEGY ELLIPTA, TZIELD, ZEPBOUND, bio-ConneKt | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error